# Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome

> **NCT02813824** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 852 (estimated)

## Conditions studied

- Lynch Syndrome

## Interventions

- **DRUG:** Acetylsalicylic acid lysinate 300 mg
- **DRUG:** Placebo (for Aspirin 300)
- **DRUG:** Acetylsalicylic acid lysinate 100 mg
- **DRUG:** Placebo 100 (for Aspirin 100)

## Key facts

- **NCT ID:** NCT02813824
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-11-14
- **Primary completion:** 2026-06-15
- **Final completion:** 2027-12-15
- **Target enrollment:** 852 (ESTIMATED)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02813824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02813824, "Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02813824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*